Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Wolchok, JD; Chiarion-Sileni, V; Rutkowski, P; Cowey, CL; Schadendorf, D; Wagstaff, J; Queirolo, P; Dummer, R; Butler, MO; Hill, AG; Postow, MA; Gaudy-Marqueste, C; Medina, T; Lao, CD; Walker, J; Márquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schöffski, P; Carlino, MS; Sandhu, S; Lebbé, C; Ascierto, PA; Long, GV; Ritchings, C; Nassar, A; Askelson, M; Benito, MP; Wang, WJ; Hodi, FS; Larkin, J.

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2025; 392(1): Nº de citas: 330 [doi:10.1056/NEJMoa2407417]

Calles, A; Alonso, M; Martín-Martorell, P; Gómez, A; de Castro, J; Martínez-Aguillo, M; Estival, A; Mosquera, J; Martínez-Banaclocha, N; Majem, M; Reyes, R; Azkona, E; Ortega, AL; Aguin, S; Santos, A; Aguilar, A; Cucurull, M; Blasco, A; Calvo, V; Isla, D; Nadal, E; Aguado, C; Sais, E; Juan-Vidal, O; Diz-Taín, M; Taus, A; Villanueva, N; Bayona, C; Amenedo, M; Mielgo, X; Arriola, E; Baena, J.

Efficacy and safety of lorlatinib in patients with ALK-and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Cancer Treatment and Research Communications. 2025; 43: Nº de citas: 2 [doi:10.1016/j.ctarc.2025.100905]

Robert C; Long GV; Larkin J; Wolchok JD; Hassel JC; Schadendorf D; Hodi FS; Lebbé C; Grob JJ; Hyngstrom JR; Wagstaff J; Chesney J; Butler MO; Bechter O; Márquez-Rodas I; Pavlick AC; Durani P; Pe Benito M; Wang P; Postow MA; Ascierto PA.

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

EUROPEAN JOURNAL OF CANCER. 2025; 214: 115119-115119 Nº de citas: 11 [doi:10.1016/j.ejca.2024.115119]

Isla, D; Alvarez, R; Arnal, M; Arriola, E; Azkarate, A; Azkona, E; García-Campelo, R; Garrido, P; Nadal, E; Ortega, AL; Carcedo, D; Crespo, M; Lavara, J; Córcoles, F; Bernabé, R.

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

JOURNAL OF MEDICAL ECONOMICS. 2024; 27(1): 1379-1387 Nº de citas: 4 [doi:10.1080/13696998.2024.2413289]

Lin, CC; Garralda, E; Schoeffski, P; Hong, DS; Siu, LL; Martin, M; Maur, M; Hui, RA; Soo, RA; Chiu, J; Zhang, T; Ma, BGT; Kyi, C; Tan, DS; Cassier, PA; Sarantopoulos, J; Weickhardt, A; Carvajal, RD; Spratlin, J; Esaki, T; Rolland, F; Akerley, W; Deschler-Baier, B; Rispoli, L; Samant, TS; Chowdhury, NR; Gusenleitner, D; Kwak, EL; Askoxylakis, V; De Braud, F.

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

OncoImmunology. 2024; 13(1): 2290787-2290787 Nº de citas: 25 [doi:10.1080/2162402X.2023.2290787]

Piedra, A; Martínez-Recio, S; Hernández, A; Morán, T; Arriola, E; Recuero-Borau, J; Cobo, M; Cordeiro, P; Mosquera, J; Fernández, M; García-Campelo, R; Calles, A; Alvarez, R; Zapata-García, M; Isla, D; Callejo, A; Iranzo, P; Serra-López, J; Barba, A; Sullivan, I; Felip, E; Majem, M.

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Frontiers in Oncology. 2024; 14: Nº de citas: 2 [doi:10.3389/fonc.2024.1510278]

Hamilton, E; Galsky, MD; Ochsenreither, S; Del Conte, G; Martín, M; De Miguel, MJ; Yu, EY; Williams, A; Gion, M; Tan, AR; Agrawal, L; Rutten, A; Machiels, JP; Cresta, S; Debruyne, PR; Hennequin, A; Moreno, V; Minchom, A; Valdes-Albini, F; Petrylak, D; Li, L; Tsuchihashi, Z; Suto, F; Cheng, FC; Kandil, M; Barrios, D; Hurvitz, S.

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

CLINICAL CANCER RESEARCH. 2024; 30(24): 5548-5558 Nº de citas: 33 [doi:10.1158/1078-0432.CCR-24-1513]

Jhaveri, KL; Lim, E; Jeselsohn, R; Ma, CX; Hamilton, EP; Osborne, C; Bhave, M; Kaufman, PA; Beck, JT; Sanchez, LM; Parajuli, R; Wang, HC; Tao, JJ; Im, SA; Harnden, K; Yonemori, K; Dhakal, A; Neven, P; Aftimos, P; Pierga, JY; Lu, YS; Larson, T; Jerez, Y; Sideras, K; Sohn, J; Kim, SB; Saura, C; Bardia, A; Sammons, SL; Bacchion, F; Li, YJ; Yuen, E; Estrem, ST; Rodrik-Outmezguine, V; Nguyen, B; Ismail-Khan, R; Smyth, L; Beeram, M.

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(35): Nº de citas: 29 [doi:10.1200/JCO.23.02733]

Neven, P; Stahl, N; Vidal, M; Martin, M; Kaufman, PA; Harbeck, N; Hunt, KK; Carter, S; Bidard, FC; Fasching, PA; Aftimos, P; Wheatley, D; Hamilton, E; Aft, R; Kulkarni, S; Schmid, P; Bhave, M; Ismail-Khan, R; Karacsonyi, C; Estrem, ST; Nguyen, B; Ozbek, U; Yuen, E; Rodrik-Outmezguine, V; Ciruelos, E.

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

CLINICAL CANCER RESEARCH. 2024; 30(23): 5304-5313 Nº de citas: 6 [doi:10.1158/1078-0432.CCR-24-2113]

Salazar, J; Arranz, MJ; Martin-Broto, J; Bautista, F; Martínez-García, J; Martínez-Trufero, J; Vidal-Insua, Y; Echebarria-Barona, A; Díaz-Beveridge, R; Valverde, C; Luna, P; Vaz-Salgado, MA; Blay, P; Alvarez, R; Sebio, A.

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Pharmaceutics. 2024; 16(12): Nº de citas: 5 [doi:10.3390/pharmaceutics16121585]

de la Haba-Rodríguez, JR; Mínguez, P; Rojo, F; Martín, M; Alba, E; Servitja, S; Prat, A; Pérez-Fidalgo, JA; Gavilá, J; Morales, C; Rodriguez-Lescure, A; Herrero, C; Peña-Enriquez, R; Herranz, J; Hernando, C; Hernández-Blanquisett, A; Guil-Luna, S; Martinez, MT; Blanch, S; Caballero, R; Martín, N; Pollán, M; Guerrero-Zotano, A; Bermejo, B.

Gestational breast cancer: distinctive molecular and clinico-epidemiological features

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. 2024; 29(1): Nº de citas: 4 [doi:10.1007/s10911-024-09571-3]

García-Alfonso, P; Elez, E; Soto-Alsar, J; Páez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Gómez-España, MA; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; Grávalos, C; González-Flores, E; Guix, M; Paredes, BG; Reina, JJ; Mowbray, JRR; Sastre, J; Aranda, E.

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

ESMO Open. 2024; 9(12): Nº de citas: 1 [doi:10.1016/j.esmoop.2024.103986]

Cánovas, MS; Robles, JL; Adoamnei, E; Lavin, DC; Pedroche, CD; Salvans, EC; Verduguez, TQ; Verdejo, FJG; Solís, MC; Adrián, SG; Portero, BO; Fernández, AG; Coloma, CS; Prado, MPMD; Mendiola, J; Martín, AJM.

Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

European Journal of Internal Medicine. 2024; 130: 98-105 Nº de citas: 5 [doi:10.1016/j.ejim.2024.08.005]

Gutiérrez, F; Padilla, S; García-Abellán, J; de la Tabla, AGO; Ledesma, C; Masiá, M.

Cancer screening in people with HIV: Implementation in clinical practice and barriers perceived by medical specialists in Spain

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2024; 42(10): 563-569 Nº de citas: 3 [doi:10.1016/j.eimc.2023.10.014]

Tolaney, SM; Tung, N; Wolff, AC; DeMichele, A; Cejalvo, JM; Martínez-Sáez, O; Pascual, T; Waks, AG; Martín, M; Ciruelos, E; Harbeck, N; Carey, LA; Cortés, J; Curigliano, G; Prat, A.

HER2DX genomic test in early-stage HER2-positive breast cancer

ESMO Open. 2024; 9(12): Nº de citas: 22 [doi:10.1016/j.esmoop.2024.103987]

Frazer, R; Arranz, JA; Estévez, SV; Parikh, O; Krabbe, LM; Vasudev, NS; Doehn, C; Marschner, N; Waddell, T; Ince, W; Goebell, PJ.

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

Current Oncology Reports. 2024; 26(12): 1639-1650 Nº de citas: 2 [doi:10.1007/s11912-024-01613-7]

García-Alfonso, P; Jimenez-Fonseca, P; Soto-Alsar, J; Baraibar, I; Santos, C; La Casta, A; Ghanem, I; Cortijo, G; Méndez, A; Pazo-Cid, R; Vera, R; Melián, M; Alcaide, J; Graña, B; Páez, D; Gallego, I; Lobo, M; Borregón, M; Montes, A; de Castro, E; Carmona-Bayonas, A; Aranda, E.

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

ONCOLOGIST. 2024; 30(8): Nº de citas: 4 [doi:10.1093/oncolo/oyae300]

Alonso-Gordoa, T; Jimenez-Fonseca, P; Martinez-Trufero, J; Navarro, M; Porras, I; Rubió-Casadevall, J; Valles, MA; Basté, N; Hernando, J; Docampo, LI.

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Clinical & Translational Oncology. 2024; 26(11): 2902-2916 Nº de citas: 4 [doi:10.1007/s12094-024-03736-6]